Voyager Therapeutics, Inc. (NASDAQ:VYGR) has received an average rating of “Buy” from the thirteen analysts that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $30.33.
A number of analysts have weighed in on VYGR shares. Stifel Nicolaus reissued a “buy” rating and set a $31.00 target price (up from $20.00) on shares of Voyager Therapeutics in a report on Monday. ValuEngine raised shares of Voyager Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Raymond James Financial, Inc. started coverage on shares of Voyager Therapeutics in a report on Thursday, October 12th. They set an “outperform” rating and a $35.00 target price on the stock. Zacks Investment Research cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Finally, Chardan Capital reissued a “hold” rating on shares of Voyager Therapeutics in a report on Sunday, September 10th.
In related news, insider Bernard Ravina sold 16,470 shares of the stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $12.87, for a total value of $211,968.90. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last ninety days, insiders sold 32,940 shares of company stock worth $490,092. Corporate insiders own 8.00% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the stock. Raymond James Financial Services Advisors Inc. acquired a new stake in shares of Voyager Therapeutics in the 3rd quarter worth about $1,122,000. Nationwide Fund Advisors increased its holdings in shares of Voyager Therapeutics by 81.5% in the 3rd quarter. Nationwide Fund Advisors now owns 19,779 shares of the company’s stock worth $407,000 after acquiring an additional 8,884 shares during the period. California State Teachers Retirement System increased its holdings in shares of Voyager Therapeutics by 8.4% in the 2nd quarter. California State Teachers Retirement System now owns 25,811 shares of the company’s stock worth $231,000 after acquiring an additional 2,000 shares during the period. State Street Corp increased its holdings in shares of Voyager Therapeutics by 11.8% in the 2nd quarter. State Street Corp now owns 184,526 shares of the company’s stock worth $1,653,000 after acquiring an additional 19,471 shares during the period. Finally, DAFNA Capital Management LLC increased its holdings in shares of Voyager Therapeutics by 187.2% in the 2nd quarter. DAFNA Capital Management LLC now owns 204,808 shares of the company’s stock worth $1,835,000 after acquiring an additional 133,488 shares during the period. 40.74% of the stock is currently owned by institutional investors and hedge funds.
Voyager Therapeutics (NASDAQ:VYGR) traded up 0.37% on Thursday, reaching $21.54. 131,067 shares of the company’s stock were exchanged. The firm’s market capitalization is $579.49 million. Voyager Therapeutics has a 1-year low of $8.10 and a 1-year high of $25.99. The stock’s 50 day moving average price is $19.30 and its 200 day moving average price is $12.04.
Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.73) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.11). The company had revenue of $1.18 million for the quarter, compared to the consensus estimate of $3.27 million. Voyager Therapeutics had a negative net margin of 712.22% and a negative return on equity of 46.15%. On average, analysts expect that Voyager Therapeutics will post ($2.87) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Voyager Therapeutics, Inc. (VYGR) Given Consensus Recommendation of “Buy” by Analysts” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.dispatchtribunal.com/2017/10/26/voyager-therapeutics-inc-vygr-given-consensus-recommendation-of-buy-by-analysts.html.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.